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Abstract
Background: Given the prevalence of untreated pain among cancer patients, there have been calls for more and
better research in the domain. Increasingly, calls for less waste and more optimal use of trial data collected are
being made. Waste of data includes non-optimal statistical analysis and non-presentation of interpretable effect size
as a measure of effectiveness of an intervention which also enable comparisons across studies.
Methods: We reviewed the recent literature on randomised trials on longitudinal cancer pain to identify sources of
loss of data information by collecting material on the nature of outcomes collected, analysed, the method of
analysis and what was presented as a result of the trial. Illustrated with real data, we propose some guidelines on
how to adequately analyse longitudinal data and report the results using mixed models.
Results: We identified some major source of data information loss, one of which is the transformation of a
continuous pain outcome. Not adjusting for the collected outcome baseline value is moreover a source of bias.
Multiple testing by analysing the data cross-sectionnally at each time-point leads to loss of information and power.
Finally, effect sizes reflecting the effectiveness of the intervention were never reported.
Conclusions: We identified several sources of information loss in the way longitudinal trials on pain were analysed
and reported. However these problems could be easily solved by using regression methods like mixed models and
presenting regression parameters to provide a concrete quantitative effect of the intervention.
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Background
According to the ESMO Guideline working group [1]
over 80 % of cancer patients with advanced metastatic
disease suffer from pain. A vast literature [2–4] reports
the inadequacy of pain treatment among these patients
despite numerous initiatives and recommendations [5–8].
Therefore high quality trials assessing the efficacy of anal-
gesic drugs and treatment strategies are required for this
population of patients. Quality research includes optimally
using all the data collected and analysing it an informative
way i.e. using the statistical method which best reflects the
effect of the intervention. Recently, it has been reported
that there were numerous examples of waste in the
running of clinical trials [9], non-optimal use of the
data collected being one of them.
Repeated measures are often collected in cancer pain
trials in order to reflect the need for lasting effects for
the patients, the speed of action, or to evaluate a time to
onset of relief. Longitudinal data allow comparisons of
the dynamic of the intervention and the control. Statis-
tical care needs to be taken because repeated measures
on the same patient are not independent. But modern
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methods of analysis which permit to analyse such data
like mixed model are now implemented in most statistical
software packages which make them easily accessible to
researchers. Advantages of mixed models include: i) the
longitudinal nature of the data can be taken into account
without loss of information as a multiple cross-sectional
analysis would do ii) data for all patients with at least one
measure post-baseline can be used for the analysis, and iii)
the exact timing of the measure can be accounted for.
Moreover the regression coefficient for group effect ob-
tained can be used to present a quantitative value of the
effect of the intervention in terms of pain measure.
Baseline pain measures need to be collected for several
reasons. One is that patients with different levels of pain
may be affected differently by the intervention. With this
information missing, the real effect of the intervention
might be over or underestimated [10]. Also because of
the reduction to the mean (patients with higher pain
score will see larger effects) baseline measures need to
be controlled for in a regression model [11] and this des-
pite an appropriate randomisation. While neither men-
tioning either baseline explicitly nor longitudinal studies,
the IMMPACT [12] recommendations include reporting
absolute and relative differences of pain measures from
baseline.
The aim of this paper is two-fold. The first is to report
the results of a systematic review on how longitudinal
data in cancer pain in randomised controlled trials
(RCT’s) is analysed. The aim is to see if there is any evi-
dence of systematic loss of information due to subopti-
mal use of the data. Secondly, we provide guidelines on
how to make the best use of the data collected and how
to report results using regression parameters.
Methods
In October 2013, the databases Medline, Medpilot,
Cochrane Library, Scopus/SciVerse were searched for ar-
ticles reporting RCT’s or protocols for RCT’s on the
treatment of pain in cancer patients. RCT’s identified on
pain produced by cancer diagnostic procedures and
studies on postoperative pain were excluded from the re-
view, as were systematic reviews. The languages were
limited to English, French and German due to limited
resources. Studies reporting a secondary analysis of RCT
data were excluded as well as if an assessment of pain
was made only as a part of a measurement of quality of
life. In order to reflect recent practices we restricted our
search to articles published in 2009 or later. The review
was later updated to include articles until the year 2015.
The MeSH terms are given in appendix. All extracted
studies were screened for eligibility independently by
two of the authors by reading the abstract. The full text
of all eligible studies was obtained. The reporting of this
review follows the PRISMA statement checklist [13].
Data were collected using a form piloted for
consistency. Data were collected independently by two
of the authors and when entries were in disagreement,
the articles were further checked. The agreement consid-
ered good if any differences between reviewers could be
resolved after checking the articles. The full list of items
extracted from the studies can be seen in Tables 1, 2, 3.
It included background information on the study,
whether a baseline measure of pain was collected,
whether the data was analysed longitudinally or cross-
sectionally at each time-point and the method of statistical
analysis. We also considered if the data was analysed as
continuous or in a dichotomised form, and whether base-
line measures were adjusted for.
This work is a systematic review of the literature and
contains no research on humans; therefore no ethical
approval is required. Results of the review are presented
in descriptive tables with absolute and relative numbers
of articles for each item. The discussion is illustrated
with data from the Treat and Screen study [14], a RCT
to evaluate the effectiveness of pain treatment protocol
and screening for patients with head and neck cancer. All
analysis were performed using Stata 12 (StataCorp. 2011).
Results
We identified 74 eligible studies, three of which were
protocols. Agreement between the two reviewers was
good. The complete flowchart is given in Fig. 1 and a
table summarising the data collected for each article in
provided as Additional file 1. The study characteristics
are presented in Table 1. Most studies identified con-
cerned background pain (70/74) and only four focused
on breakthrough pain. More than two thirds (69 %, 41/
74) collected a pain measure as a primary outcome
measure. The Brief Pain Inventory was the most used in-
strument (23/74, 31 %) followed by a visual analogue
scale (VAS) (21/74, 28 %) and numerical rating scale
(17/74, 23 %). However the continuous pain outcome is
analysed as such in only 60 % (44/74) of studies, other
using a dichotomised version (17/74), a difference from
baseline (18/74) or an aggregated value (7/74). All re-
sults regarding the statistical analysis are presented in
Table 2. Only 38 % (28/74) of studies performed a longi-
tudinal analysis of the data. Other studies analysed the
data cross-sectionnally (27/74), mostly at each measure
time-point, thus losing the longitudinal information in-
cluded in the data. Moreover repeated cross sectional
analysis constitutes multiple testing for which only four
studies reported using a correction. In the remainder,
aggregated data or only one measure time-point was
analysed thus losing completely the longitudinal nature
of the study.
The data presented (for the 71 studies which were not
protocols) included mostly mean and standard deviations
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at each time-point and for each group but in only one lon-
gitudinally analysed study were quantitative effects of the
intervention presented as results of the trial.
Baseline data was collected in most, 91 % (67/74), but
not all studies. In only 40 % (27/67) of studies, the
method of adjustment for baseline data was reported in
the Methods section. Moreover in 40 % of studies, it is
either not known or it is clear that the baseline data was
not adjusted for.
Discussion
While some studies used an appropriate method for the
analyse of longitudinal pain data, the present review re-
vealed several sources of loss of information in longitu-
dinal RCT’s on cancer pain. This means that there is a
non-optimal use of the data collected is made. Thus
more accurate information on the effect of an interven-
tion is available but not known. If the choice of method
of analysis does not necessarily affect the success of a
trial if the latest is based on the significance of a statis-
tical test, it affects the effect size and standard deviation
presented. In meta-analysis, the cumulated loss of infor-
mation could potentially make a difference in the rec-
ommendation made. This issue could be further
researched but is not within the scope of this paper.
After reviewing the list of highlighted problems–see also
Table 4 for a summary–we show how they can be easily
solved and how a researcher can present the output of
interest without compromising on statistical optimality.
Information loss occurs when the continuous outcome
collected is transformed before being analysed. Aggre-
gated data is such that all the measures taken at different
time-points on one patient are summarized to one value.
This way the longitudinal nature of the data is lost, and
either patients with missing data are left out or the ag-
gregated values include unequal time-points leading to
the outcome having varying meaning between patients.
Dichotomisation is usually done when the primary out-
come is the proportion of responders. Dichotomisation
is a problematic practice because among other issues, it
leads to a loss of power [15, 16]. This means that the
number of patients to include in the study is much larger
than if the continuous outcome was used in the primary
analysis. Responder analysis or time-to-onset in pain stud-
ies should only be performed as a secondary analysis.
In half of the studies reviewed baseline outcome values
were either not collected or not included in the analysis.
As mentioned earlier adjusting for baseline data was ne-
cessary to control for the reduction to the mean and to
obtain unbiased estimate of the effect of the intervention
if it were to affect patients with different level of pain
differently.
Analysing the data cross-sectionnally raises several is-
sues. The first one is that the longitudinal nature of the
data can only be accounted for heuristically by comparing
the differences obtained at various time-points. Statisti-
cally, this involves multiple testing which needs to be cor-
rected for therefore reducing the power. Also information
Table 1 Description of studies
Pain outcome Primary only 46 % (34/74)
Secondary only 22 % (16/74)
Primary and secondary 23 % (17/74)
Unclear 9 % (7/74)
Primary pain outcome collected NRSa 23 % (17/74)
VASb 28 % (21/74)
Brief Pain Inventory 31 % (23/74)
Other instruments 18 % (13/74)
Number of groups Two 87 % (64/74)
Number of patients Median (range) 80 (9–2046)
Type of study Parallel design 43 % (32/74)
Comparison placebo/usual care 57 % (42/74)
Cross-over design 18 % (13/74)
Duration of follow-up Under24h 16 % (12/74)
Patient dependent 7 % (5/74)
Other: median (range) of duration 7 (1–260) weeks
Type of pain episodes Breakthrough 5 % (4/74)
Background 95 % (70/74)
a Numerical rating scale
b Visual analogue scale
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on individual trajectories is lost. Some studies reported
analysing difference from baseline in a longitudinal model.
There are some conceptual difficulties in doing so because
a difference in pain intensity between Week 1 and baseline
and between Week 2 cannot necessarily be considered the
same outcome. Instead the baseline outcome value should
be adjusted for in the model. This review has made it clear
that the method of analysis was not always the one which
was making the best use of all the data available mostly
by ignoring its longitudinal nature but also by using a
method of analysis which leaves out any patient with
missing values in the outcome as does repeated meas-
ure ANOVA.
We show how to analyse longitudinal data using linear
mixed models but other regression methods exist [17].
These have the advantage of using all the data available
from all patients who have at least one measure taken post
baseline. Results of the trials should be presented as an ef-
fect size (measure of the effectiveness of the intervention)
in terms of the regression parameter for the group effect
and its standard error or confidence interval. We discuss
three approaches which can be used to answer typical
research questions in the field of chronic pain research.
A Mean Model can be used to compare overall differ-
ences in pain score post-intervention between the
groups. We have applied a mixed model on the mean
pain severity of the BPI questionnaire from the Screen
and Treat study data using time (continuous) as a covar-
iate (optional) and adjusting for baseline outcome values
to correct effect estimates for the reduction to the mean:
 Mean model: the mean difference in Mean Pain
Severity between usual care and intervention
adjusted for baseline values is 0.55 score points
(confidence interval: [−0.05, 1.14]).
If no adjustment was made for baseline values, the ef-
fect would be of 0.43, a 20 % smaller effect than with the
adjustment for baseline. Moreover, the estimate is less
precise with a larger standard error (0.35 against 0.30)
leading to a wider confidence interval. Such differences
are to be seen in the presence of inhomogeneous patient
groups, i.e. patients with high and patients with low pain
scores at baseline [11, 18].
The Slope Model is suitable when the evolution of
pain is of interest. This model provides an overall rate of
Table 2 Method of analysis
Primary pain outcome analysed NRSa or VASb measures 60 % (44/74)
Change from baseline 24 % (18/74)
Aggregated NRS or VAS 10 % (7/74)
Dichotomised outcome 23 % (17/74)
Analysis of repeated measures Cross sectional at each time-point 37 % (27/74)
longitudinal 38 % (28/74)
Method of analysis
Cross sectional t-test 44 % (12/27)
ANOVA/ANCOVA 19 % (5/27)
Non parametric test 36 % (10/27)
Correction for multiple testing due to repeated measures 15 % (4/27)
Longitudinal Mixed Model 25 % (7/28)
Repeated measure ANOVA 43 % (12/28)
GEE 1 % (4/28)
Area under the curve 7 % (2/28)
Unknown/other 10 % (3/28)
Results presented
Mean (SD) at each time-point per group 44 % (31/71c)
F values only (for ANOVA/ANCOVA) 29 % (5/17)
Proportions 59 % (5/17)
Hazard ratio, odds ratio (with CI) 23 % (4/17)
None 17 % (12/71#)
Only one study using longitudinal regression type analysis presented a parameter estimate for group effect
a Numerical rating scale
b Visual analogue scale
c From 74 studies, three were protocols
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change from baseline. It consists in comparing the slope of
pain scores over time (continuous), starting at baseline.
This is typically the situation in the treatment of break-
through pain when the treatment starts at a maximum of
pain and where the treatment with the fastest response is
the best. The difference in slope between the groups is ob-
tained by estimating time-group interactions with time
being a continuous variable. In this case, baseline is an out-
come time-point and does not need further adjustment.
 Slope model: the mean pain severity decreased by
0.060 score points per week more in the
intervention group then in the usual care group
(confidence interval [0.003, 0.117]).
Table 3 Use of baseline data in the analysis of pain outcome
Baseline data Collected 91 % (67/74)
Description of the inclusion Mentioned in Methods section 40 % (27/67)
Baseline measure included 60 % (40/67)
Not included 21 % (14/67)
Unknown 19 % (13/67)
Method of inclusion Difference from baseline (cross sectional) 76 % (13/17)
Covariate (Cross sec. and long.) 29 % (8/28)
Time-point (Long.) 30 % (7/23)
Used to compute a dichotomised outcome 41 % (7/17)
Fig. 1 PRISMA flow diagram
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Time can also be used as a categorical variable with
group-time interactions to obtain a separate group com-
parison at each time-point with adjustment for outcome
baseline values. This is a more accurate and powerful
alternative to multiple testing procedures in order to as-
sess at which time-point the difference between groups
is at its highest. This should be done as a secondary ana-
lysis after providing an overall mean difference over time
(mean model above).
 Categorical time variable: The difference in mean
pain severity at 1 month between usual care and
intervention was 0.42 [−0.36, 1.20], at 2 months the
difference was −0.25 [−0.90, 0.39] less than at 1
month and at 3 months 0.29 [−0.36, 0.95] more
than at 1 month.
Limitations
This review focused on the primary statistical analysis
and not on the adequacy of the pain measure or the re-
sults obtained. It is clear that many studies did not use a
validated instrument for chronic pain (only a third used
the Brief Pain Inventory with the vast majority of studies
using VAS od NRS in isolation ignoring the history of
pain [10]) while most longitudinal studies analysed back-
ground pain which is a form of chronic pain. This point
would require further work because of the bias incurred
from the inaccuracy of pain measures but goes beyond
the purpose of this work. This study did not show any
indication that there was a relationship between the
choice of pain measure and the method of analysis.
However further research could be perform to show if
there are any relationship between the pain measure and
the effects shown by the study.
Conclusions
Our review highlighted that the way the data was often
analysed or the results presented in the clinical trials lit-
erature on cancer pain led to loss of some of the infor-
mation present in the data collected. In order to present
the best evidence available on treatments these practices
should be avoided. Without compromising on the im-
pact and interest that research studies generate, we have
provided some indications on how methodology could
be improved. In particular we have demonstrated how to
avoid dichotomisation or multiple testing in the primary
analysis and how to present informative effect as the
result of the trial.
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Source Nature of the loss Solution
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for
Collected data not used, bias [9, 10] Adjust for baseline in a regression model
Dichotomisation of the
main continuous outcome
Loss of power, information [15, 16] Analyse the continuous outcome as primary analysis, dichotomised
outcome presented as secondary
Aggregated longitudinal
data
Loss of the longitudinal nature of the data, loss
of the treatment dynamic over time
Use a linear mixed model possibly with time as a covariate.
Cross sectional analysis at
each time-point
Multiple testing requiring a correction,
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Use a linear mixed model with categorised time with time-group
interactions.
No effect size provided No information on the magnitude of the effect
in term of outcome measure
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regression parameter for group effect with confidence interval
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